Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
WAVERLEY PHARMA Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SYNBIOTIC | 3,020 | -5,62 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC stellt erstmals Medizinalcannabis als Lutschpastille für den deutschen Markt vor | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Produkteinführung
SYNBIOTIC stellt erstmals Medizinalcannabis als Lutschpastille für den deutschen Markt vor
01.04.2025 / 15:13... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,035 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
INDIVA | 0,016 | -100,00 % | SNDL Inc.: SNDL Emerges as Canada's Leading Producer of Edibles with Indiva Acquisition | CALGARY, AB, Nov. 4, 2024 /CNW/ - SNDL Inc. (Nasdaq: SNDL) ("SNDL" or the "Company") announced today that, in the context of Indiva Limited's ("Indiva" and together... ► Artikel lesen | |
HAPPY BELLY FOOD GROUP | 0,685 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Selects TOAST to Power Growing Restaurant Portfolio | Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging food brands is pleased... ► Artikel lesen | |
CSPC PHARMA | 0,604 | -1,08 % | M Stanley Cuts CSPC PHARMA TP to $6.7, Rating Overweight | ||
TONIX PHARMACEUTICALS | 14,000 | -1,55 % | Tonix Pharmaceuticals Holding: Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year | CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial... ► Artikel lesen | |
PSYCHED WELLNESS | 0,011 | -7,08 % | Psyched Wellness Ltd.: Psyched Wellness Provides Comprehensive Investor Update | Toronto, Ontario--(Newsfile Corp. - March 14, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and... ► Artikel lesen | |
SWEET EARTH | 0,290 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 12.12.2024 | The following instruments on XETRA do have their first trading 12.12.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 12.12.2024
Aktien
1 SE0023261599 Carasent AB
2 AU0000053373... ► Artikel lesen | |
JUVA LIFE | 0,023 | -100,00 % | Juva Life Aktie: Zinspolitik belastet Ausblick | Die Juva Life Inc. zeigt zum Stichtag 18. Januar 2025 eine bemerkenswerte Stagnation im Handel. Der Aktienkurs verharrt bei 0,0000 USD, was die anhaltenden Herausforderungen des Cannabisunternehmens... ► Artikel lesen | |
MEDMEN ENTERPRISES | - | - | This Week In Cannabis: The MedMen Saga, Multi-Million-Dollar Financings, Controversies In LatAm And More | ||
LEEF BRANDS | 0,117 | +1,74 % | LEEF Brands Inc.: LEEF Brands to Become One of the First Publicly Traded Cannabis Company to Integrate Bitcoin into its Treasury Reserve via US$5 Million Bitcoin-Backed Debenture Offering | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LEEF Brands, Inc. ("LEEF" or the "Company")... ► Artikel lesen | |
NUMINUS WELLNESS | 0,027 | -100,00 % | XFRA LR23: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILNUMINUS WELLNESS... ► Artikel lesen | |
CORBUS PHARMACEUTICALS | 4,340 | -5,65 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
ZELIRA THERAPEUTICS | 0,268 | +1,52 % | ZELIRA THERAPEUTICS LIMITED: Investor Presentation | ||
CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report |